



# Osteocalcin is necessary and sufficient to maintain muscle mass in older mice

Paula Mera, Kathrin Laue, Jianwen Wei, Julian Meyer Berger, Gerard Karsenty\*

## ABSTRACT

**Objective:** A decrease in muscle protein turnover and therefore in muscle mass is a hallmark of aging. Because the circulating levels of the bone-derived hormone osteocalcin decline steeply during aging in mice, monkeys and humans we asked here whether this hormone might regulate muscle mass as mice age.

**Methods:** We examined muscle mass and strength in mice lacking osteocalcin (*Ocn*<sup>-/-</sup>) or its receptor in all cells (*Gprc6a*<sup>-/-</sup>) or specifically in myofibers (*Gprc6a<sub>Mck</sub>*<sup>-/-</sup>) as well as in 9 month-old WT mice receiving exogenous osteocalcin for 28 days. We also examined protein synthesis in WT and *Gprc6a*<sup>-/-</sup> mouse myotubes treated with osteocalcin.

**Results:** We show that osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice in part because it promotes protein synthesis in myotubes without affecting protein breakdown. We further show that treatment with exogenous osteocalcin for 28 days is sufficient to increase muscle mass of 9-month-old WT mice.

**Conclusion:** This study uncovers that osteocalcin is necessary and sufficient to prevent age-related muscle loss in mice.

© 2016 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords** Osteocalcin; Muscle mass; Aging

## 1. INTRODUCTION

With the increase of life expectancy our societies experience comes a slew of age-related diseases. The aging process is characterized for instance by changes in body composition that include a decrease in muscle mass and/or strength. This manifestation of aging known as muscle wasting [1,2], is a cause of a metabolic deregulation [3,4], and also contributes to the increased morbidity seen in the elderly because of the higher risk of falls and fractures. One of the proposed causes for this age-related decline in muscle mass is a reduced muscle protein turnover, defined as the balance between muscle protein synthesis and breakdown [5]. How protein turnover in muscle is regulated and can be affected by aging remains however, poorly understood. The recent demonstration that the bone-derived hormone osteocalcin favors muscle functions during exercise [6,7] raises the question of whether this hormone may also regulate muscle mass.

In support of this working hypothesis we note that osteocalcin favors physiological functions that like testosterone synthesis and male fertility [8,9], memory or adaptation to exercise [7,10], tend to decrease with age. At the same time the circulating levels of bioactive osteocalcin decrease rapidly and steeply in life in mice, monkeys and humans [7]. These findings were two additional incentives to ask whether osteocalcin signaling in myofibers also prevents another aspect of aging namely the decrease in muscle mass. Here we show

that osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice because it promotes protein synthesis in muscle cells. More importantly, exogenous osteocalcin is also sufficient to increase muscle mass in 10-month-old mice. These results expand the importance of the regulation of muscle physiology by bone-derived hormones and suggest novel and adapted therapies to treat age-related muscle wasting.

## 2. MATERIALS AND METHODS

### 2.1. Animal studies

*Osteocalcin* (*Ocn*<sup>-/-</sup>) mice were maintained on 129-Sv genetic backgrounds. *Gprc6a*<sup>-/-</sup>, *Gprc6a<sub>Mck</sub>*<sup>-/-</sup> and *Ocn*<sup>+/-</sup>;*Gprc6a<sub>Mck</sub>*<sup>+/-</sup> mice were maintained on 129-Sv/C57/BL6 mixed genetic background. To minimize the possible confounding effect of a different genetic background all experiments were performed using control littermates. Generation of mice harboring a *Gprc6a* conditional allele has been described [9]. For osteocalcin treatment studies 9-month-old WT 129-Sv mice (Taconic) were implanted with subcutaneous osmotic pumps (Alzet, model 1004) delivering osteocalcin (90 ng/h) for 28 days. After this period, mice were euthanized and muscles dissected for analyses of muscle mass and histology examination. Recombinant osteocalcin was purified as previously described [10]. All procedures involving mice were approved by CUMC IACUC and conform to the relevant regulatory standards.

Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA

\*Corresponding author. Department of Genetics and Development, 701W 168th Street, Room 1602A HHSC, New York, NY 10032, USA. Fax: +1 212 923 2090. E-mail: [gk2172@cumc.columbia.edu](mailto:gk2172@cumc.columbia.edu) (G. Karsenty).

Received June 28, 2016 • Revision received July 8, 2016 • Accepted July 10, 2016 • Available online 16 July 2016

<http://dx.doi.org/10.1016/j.molmet.2016.07.002>

## 2.2. Histology

Examination of muscle histology was done using 5- $\mu$ m thick formalin-fixed, paraffin-embedded tissue sections stained with hematoxylin and eosin (H&E) at the Molecular Pathology Core at UT Southwestern Medical Center.

## 2.3. Myoblasts culture and differentiation

Culture of mouse skeletal muscle myoblasts was performed as described [7,11], using 15- to 20-day-old mice. Myoblasts were cultured until 80% confluent and then differentiated into myotubes in DMEM supplemented with 5% horse serum.

For in vitro inactivation of *Gprc6a*, myoblasts from *Gprc6a*<sup>-/-</sup> mice and WT controls were isolated and differentiated as above.

## 2.4. Protein synthesis

Protein synthesis was determined as the incorporation of <sup>3</sup>H-tyrosine to cellular proteins. In brief, myotubes were differentiated for 4 days in 24-well plates. The day of the experiment cells were washed and incubated in serum free-high glucose DMEM 0.1% BSA for 4 h. Next, 2  $\mu$ Ci/well of <sup>3</sup>H-tyrosine with either vehicle or osteocalcin were added to each well. Cells were then incubated for 2 h following 2 washes with 1  $\times$  PBS. Next, cellular proteins were precipitated with 10% TCA and radioactivity measured in the precipitated fraction. Results were corrected using the protein concentration in each well.

## 2.5. Western blot

To detect total and phosphorylated mTOR, S6K1, Raptor and GAPDH proteins were resolved on 8% acrylamide Tris gels. Western blot analyses were performed according to standard protocols. All antibodies used were from Cell Signaling: anti-phospho(Thr389)-S6K1 (#9205), anti-S6K1 (#2708), anti-phospho(Ser2448)-mTOR (#2971), anti-mTOR (#2972), anti-Raptor (#2280), anti-GAPDH (#2118).

## 2.6. Blood and urine measurements

Urine 3-methylhistidine (3MH) was measured as previously described in Ref. [12]. Serum osteocalcin levels were measured using an ELISA assay as previously described in Ref. [13].

## 2.7. Statistics

All data presented as mean  $\pm$  SEM. Statistical analyses were performed using unpaired, two-tailed Student's test for comparison between two groups and ANOVA tests for experiments involving more than two groups.

## 3. RESULTS

### 3.1. Osteocalcin is necessary to maintain muscle mass in adult mice

The recent identification of osteocalcin as a regulator of muscle function during exercise [7] raised the question of whether this hormone regulates any other aspect of muscle biology. This question is also prompted by the fact that circulating osteocalcin levels plummet with age [7].

One of the most common manifestations of aging in muscle is the decrease in muscle mass and/or strength. To test whether osteocalcin is a regulator of muscle mass in adult mice, we analyzed the weight of hindlimb muscles (soleus, EDL, gastrocnemius and quadriceps) in 6-month-old *Ocn*<sup>-/-</sup> and WT littermates. Because osteocalcin promotes testosterone synthesis specifically in testes but not in ovaries, *Ocn*<sup>-/-</sup> male mice have lower testosterone levels than WT littermates [9]. Given the influence of testosterone in muscle mass [14] and to

avoid this confounding factor all experiments were performed in female mice. These investigations revealed the existence of a significant decrease in the weight of soleus and gastrocnemius muscles and overall a decrease in body weight in *Ocn*<sup>-/-</sup> mice when compared to WT littermates (Figure 1A,B). This decrease in muscle mass in *Ocn*<sup>-/-</sup> mice was explained, at least in part, by a decrease in the cross-section area of the myofibers (Figure 1C). Since aging can decrease muscle strength we also analyzed this parameter in 12 month-old *Ocn*<sup>-/-</sup> mice. However, muscle strength measured as the peak amount of force applied by a mouse in grasping a pull bar, was the same in 12-month-old *Ocn*<sup>-/-</sup> and WT littermates (Figure 1D). This result suggests that osteocalcin favors maintenance of muscle mass but does not affect muscle strength in a measurable manner in older mice.


### 3.2. Osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice

The observation that osteocalcin is necessary to maintain muscle mass in adult mice raised the question as to whether this function of osteocalcin occurs following its signaling through its only identified receptor, GPRC6A [9]. When analyzed at 12 months of age, mice lacking *Gprc6a* in all cells (*Gprc6a*<sup>-/-</sup>) showed a significant decrease in muscle and body weight (Figure 2A,B). Because *Gprc6a* is expressed in myofibers and osteocalcin signals through this receptor to regulate muscle function during exercise [7], we next tested whether older mice lacking *Gprc6a* specifically in myofibers (*Gprc6a*<sup>Mck</sup><sup>-/-</sup>) presented any abnormality in the weight of their hindlimb muscles. The specificity and efficiency of *Mck*-Cre-mediated *Gprc6a* inactivation in *Gprc6a*<sup>Mck</sup><sup>-/-</sup> mice has been previously reported [7]. At 12 months of age, *Gprc6a*<sup>Mck</sup><sup>-/-</sup> mice showed a significant decrease in muscle weight when compared to control littermates, although their body weight was normal (Figure 2C,D). This latter result indicates that osteocalcin regulates muscle mass independently of its effect on energy metabolism [7,15]. That a similar decrease in muscle weight was observed in 12-month-old compound mutant mice lacking one allele of *Osteocalcin* and one allele of *Gprc6a* specifically in myofibers (*Ocn*<sup>+/-</sup>; *Gprc6a*<sup>Mck</sup><sup>+/-</sup>) (Figure 2E), provide a direct genetic evidence that osteocalcin is the main ligand of GPRC6A in myofibers responsible of its regulation of muscle mass.

### 3.3. Osteocalcin favors protein synthesis in myotubes

In an effort to understand the molecular bases of osteocalcin regulation of muscle mass in mice we tested whether osteocalcin regulates muscle protein synthesis or breakdown, because a decrease in muscle protein turnover has been previously associated with a loss of muscle mass [5,16–18].

Urinary elimination of 3MH, a byproduct of the degradation of structural proteins in muscle and a biomarker of protein breakdown [19], was similar in *Ocn*<sup>-/-</sup> and WT mice thus ruling out that osteocalcin regulates protein degradation in muscle (Figure 3A). That osteocalcin increased in a dose-dependent manner incorporation of <sup>3</sup>H-tyrosine into proteins of WT but not *Gprc6a*<sup>-/-</sup> myotubes, suggests that osteocalcin favors protein synthesis in these cells (Figure 3B–C). The importance of the mTOR complex for protein synthesis led us to ask whether the ability of osteocalcin to favor protein synthesis in myofibers relies in part on the activation of this complex [16,20]. We observed that osteocalcin induced phosphorylation of S6K1, an mTOR target protein, at Thr389 in WT myotubes (Figure 3C). This effect was abolished by Torin1, an inhibitor of mTOR signaling, or by the inactivation of the regulatory-associated protein of mTOR (Raptor) (Figure 3D,E). Taken together these data indicate that osteocalcin



**Figure 1: Osteocalcin is necessary to maintain muscle mass in adult mice.** (A) Weight of hindlimb muscles and (B) body weight in 6 month-old *Ocn*<sup>-/-</sup> female mice and WT littermates. (C) Representative histology and measurement of the cross section area (CSA) of the muscle fibers in 6 month-old *Ocn*<sup>-/-</sup> female mice and WT littermates. (D) Muscle strength determined as the maximal grip force in 12 month-old *Ocn*<sup>-/-</sup> female mice and WT littermates.

promotes protein synthesis in myotubes. This function of osteocalcin signaling in myofibers can explain why this hormone is necessary for the maintenance of muscle mass in aging mice.

### 3.4. Exogenous osteocalcin is sufficient to increase muscle mass in older mice


The fact that osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice and that its levels decrease dramatically in mice during aging, immediately raises the following question: Can exogenous osteocalcin increase muscle mass in older mice? To answer this question we implanted osmotic mini-pumps that delivered subcutaneously recombinant mouse uncarboxylated osteocalcin (osteocalcin) for 28 days (90 ng/h) to 9-month-old WT mice that have already low osteocalcin circulating levels [7]. This chronic delivery of osteocalcin increased significantly osteocalcin circulating levels and muscle weight in 10-month-old mice (Figure 4A,B). This was explained in part by an increase in the cross-section area of the muscle fibers (Figure 4C). Muscle strength was the same in vehicle- and osteocalcin-treated mice (Figure 4D). These results indicate that exogenous osteocalcin has the ability to increase muscle mass in older mice.

## 4. DISCUSSION

This study reveals that the bone-derived hormone osteocalcin is necessary to maintain muscle mass in older mice in part because it promotes protein synthesis in myotubes. Furthermore, exogenous osteocalcin is sufficient to increase muscle mass in aging mice. During aging the loss of muscle mass is believed to be due in part to a progressive decrease in the myofibers cross-section area. Several mechanisms have been proposed to explain this phenomenon [21]. Those include age-related intrinsic changes in muscle properties, age-related decrease in physical activity and in the circulating levels of

anabolic hormones and growth factors [22–24]. The fact that osteocalcin positively regulates exercise capacity and that its levels decrease sharply during aging [7] raised the prospect that osteocalcin may regulate muscle mass. By analyzing mutant mice lacking *Osteocalcin* or its receptor, *Gprc6a*, specifically in myofibers we have shown here that osteocalcin signaling in myofibers is necessary to maintain muscle mass in mice as they age. The fact that this regulation of muscle mass by osteocalcin signaling in myofibers cannot be detected in young mice [7] indicates that other mechanisms besides osteocalcin signaling are at work to maintain muscle mass in young mice. Circulating osteocalcin decreases drastically with age. As such, we also show here that administration of exogenous osteocalcin to older mice increases muscle mass and the myofiber cross-section area. Thus, based on these results it appears that osteocalcin signaling in myofibers is both necessary and sufficient to maintain muscle mass in older mice. While muscle mass was consistently decreased in the larger muscle types analyzed the phenotype was less consistent in small muscle types. This can be explained, in part by the technical difficulty of dissecting small muscles, such as the soleus with precision. However, this observation also intimates the existence of other mechanisms that work with osteocalcin to dictate muscle mass in young and older mice.


The maintenance of muscle mass depends on the balance of anabolic (protein synthesis) and catabolic (muscle breakdown) events which together determine the levels of muscle proteins. We failed to record any influence of osteocalcin on protein breakdown in muscle. In contrast we observed that osteocalcin signaling in myofibers favors protein synthesis. Other muscle anabolic hormones activate the PI3K/Akt/mTOR pathway to stimulate protein synthesis and muscle hypertrophy [25]. Consistent with this notion and with the fact that osteocalcin is necessary and sufficient to stimulate Akt phosphorylation in muscle during exercise [7], we show here that




**Figure 2: Osteocalcin signaling in myofibers is necessary to maintain muscle mass in older mice.** (A) Weight of hindlimb muscles and (B) body weight in 12 month-old *Gprc6a*<sup>-/-</sup> female mice and WT littermates. (C) Weight of hindlimb muscles and (D) body weight in 12 month-old *Gprc6a*<sup>Mck-/-</sup> female mice and WT littermates. (E) Weight of hindlimb muscles and (F) body weight in 12 month-old compound mutant mice *Ocn*<sup>+/-</sup>;*Gprc6a*<sup>Mck+/-</sup> female mice and control littermates (control group includes WT, *Gprc6a*<sup>fl/fl</sup>, *Gprc6a*<sup>+/+</sup> and *Mck-Cre* transgenic mice).

osteocalcin promotes protein synthesis in mouse myotubes and that this function requires activation of the mTOR pathway, presumably through the activation of Akt. This mode of action of osteocalcin in myofibers is reminiscent of its action in pancreatic islets, Leydig cells of the testes and the brain where it favors protein synthesis and/or cell proliferation [9,26].

The study of the mechanisms underlying age-related muscle loss aims at identifying targets for drug discovery and for the development of novel and efficient treatments to combat muscle wasting [21]. Classical physiology experiments have revealed that exposure of old muscle to the blood of young mouse restored the regenerative potential of muscle that was impaired with aging, suggesting that changes in



**Figure 3: Osteocalcin increases protein synthesis in WT myotubes.** (A) Urine levels of 3-methylhistidine (3MH) in *Ocn*<sup>-/-</sup> female mice and WT littermates. (B) Protein synthesis in WT mouse myotubes as measured by <sup>3</sup>H-Tyrosine incorporation into cellular protein and in (C) *Gprc6a*<sup>-/-</sup> myotubes treated for 2 h with different dose of osteocalcin (Ocn). (D) Phosphorylation of S6K1 in WT mouse myotubes treated for 30 min with different dose of Ocn. (E) Phosphorylation of S6K1 in WT and *raptor*<sup>-/-</sup> mouse myotubes treated for 30 min with Ocn (10 ng/ml). (F) Phosphorylation of mTOR and S6K1 in WT mouse myotubes treated for 30 min with Ocn (10 ng/ml) in the presence or absence of the mTOR inhibitor Torin 1.



**Figure 4: Exogenous osteocalcin is sufficient to increase muscle mass in older mice.** (A) Weight of hindlimb muscles and (B) body weight of 10 month-old WT female mice receiving vehicle or osteocalcin (Ocn) for 28 days. (C) Representative histology and measurement of the cross section area (CSA) of the muscle fibers in 10 month-old WT female mice receiving vehicle or Ocn for 28 days. (D) Circulating Ocn levels in 10 month-old WT female mice receiving vehicle or Ocn for 28 days. (E) Muscle strength determined as the maximal grip force in 10 month-old WT female mice receiving vehicle or Ocn for 28 days.



circulating factors may be responsible for the deleterious effect of aging on muscle mass [27–29]. The recent discovery that osteocalcin levels plummet early in life in mice, monkeys and humans and the fact that this hormone regulates muscle function during exercise and muscle mass as mice age identify this hormone as a promising candidate for the treatment of muscle wasting.

## ACKNOWLEDGEMENTS

We thank Dr. J. Rathmacher for measurement of 3MH, J. Shelton for muscle histological analyses. This work was supported by grants from the NIH 5R01AR045548, PO1AG032959 (GK) an Ellison Senior Scholar Award (GK) and an EMBO postdoctoral fellowship (K.L.).

## AUTHORS' CONTRIBUTION

P.M. and G.K. conceived the study; P.M., K.L., J.W. and J.B. performed experiments; P.M. and G.K. wrote the manuscript.

## CONFLICT OF INTERESTS

Authors declare no conflict of interest.

## REFERENCES

- [1] Novotny, S.A., Warren, G.L., Hamrick, M.W., 2015. Aging and the muscle-bone relationship. *Physiology (Bethesda)* 30(1):8–16.
- [2] Visser, M., 2009. Towards a definition of sarcopenia—results from epidemiologic studies. *The Journal of Nutrition, Health & Aging* 13(8):713–716.
- [3] Janssen, I., Ross, R., 2005. Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. *The Journal of Nutrition, Health & Aging* 9(6):408–419.
- [4] Chung, J.H., Hwang, H.J., Han, C.H., Son, B.S., Kim do, H., Park, M.S., 2015. Association between sarcopenia and metabolic syndrome in chronic obstructive pulmonary disease: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011. *COPD* 12(1):82–89.
- [5] Bross, R., Storer, T., Bhasin, S., 1999. Aging and muscle loss. *Trends Endocrinology & Metabolism* 10(5):194–198.
- [6] Karsenty, G., Olson, E.N., 2016. Bone and muscle endocrine functions: unexpected paradigms of inter-organ communication. *Cell* 164(6):1248–1256.
- [7] Mera, P., Laue, K., Ferron, M., Confavreux, C., Wei, J., Galán-Diez, M., et al., 2016. Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise. *Cell Metabolism* 23(6):1078–1092.
- [8] Oury, F., Ferron, M., Huizhen, W., Confavreux, C., Xu, L., Lacombe, J., et al., 2013. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. *The Journal of Clinical Investigation* 123(6):2421–2433.
- [9] Oury, F., Sumara, G., Sumara, O., Ferron, M., Chang, H., Smith, C.E., et al., 2011. Endocrine regulation of male fertility by the skeleton. *Cell* 144(5):796–809.
- [10] Oury, F., Khirmian, L., Denny, C.A., Gardin, A., Chamouni, A., Goeden, N., et al., 2013. Maternal and offspring pools of osteocalcin influence brain development and functions. *Cell* 155(1):228–241.
- [11] Gharaibeh, B., Lu, A., Tebbets, J., Zheng, B., Feduska, J., Crisan, M., et al., 2008. Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the preplate technique. *Nature Protocols* 3(9):1501–1509.
- [12] Aranibar, N., Vassallo, J.D., Rathmacher, J., Stryker, S., Zhang, Y., Dai, J., et al., 2011. Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling. *Analytical Biochemistry* 410(1):84–91.
- [13] Ferron, M., Wei, J., Yoshizawa, T., Ducy, P., Karsenty, G., 2010. An ELISA-based method to quantify osteocalcin carboxylation in mice. *Biochemical and Biophysical Research Communications* 397(4):691–696.
- [14] Sheffield-Moore, M., Urban, R.J., 2004. An overview of the endocrinology of skeletal muscle. *Trends in Endocrinology and Metabolism* 15(3):110–115.
- [15] Lee, N.K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J.D., Confavreux, C., et al., 2007. Endocrine regulation of energy metabolism by the skeleton. *Cell* 130(3):456–469.
- [16] Bentzinger, C.F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J.B., Oliveri, F., et al., 2008. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell Metabolism* 8(5):411–424.
- [17] Ohanna, M., Sobering, A.K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., et al., 2005. Atrophy of S6K1(–/–) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. *Nature Cell Biology* 7(3):286–294.
- [18] Shima, H., Pende, M., Chen, Y., Fumagalli, S., Thomas, G., Kozma, S.C., 1998. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. *The EMBO Journal* 17(22):6649–6659.
- [19] Lou, M.F., 1979. Human muscular dystrophy: elevation of urinary dimethylarginines. *Science* 203(4381):668–670.
- [20] Laplante, M., Sabatini, D.M., 2012. mTOR signaling. *Cold Spring Harbor Perspectives in Biology* 4(2).
- [21] Egerman, M.A., Glass, D.J., 2014. Signaling pathways controlling skeletal muscle mass. *Critical Reviews in Biochemistry and Molecular Biology* 49(1):59–68.
- [22] Chahal, H.S., Drake, W.M., 2007. The endocrine system and ageing. *The Journal of Pathology* 211(2):173–180.
- [23] Plant, D.R., Lynch, G.S., 2002. Excitation-contraction coupling and sarcoplasmic reticulum function in mechanically skinned fibres from fast skeletal muscles of aged mice. *The Journal of Physiology* 543(Pt 1):169–176.
- [24] van den Beld, A.W., de Jong, F.H., Grobbee, D.E., Pols, H.A., Lamberts, S.W., 2000. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. *The Journal of Clinical Endocrinology and Metabolism* 85(9):3276–3282.
- [25] Rommel, C., Bodine, S.C., Clarke, B.A., Rossman, R., Nunez, L., Stitt, T.N., et al., 2001. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nature Cell Biology* 3(11):1009–1013.
- [26] Wei, J., Hanna, T., Suda, N., Karsenty, G., Ducy, P., 2014. Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a. *Diabetes* 63(3):1021–1031.
- [27] Carlson, B.M., Faulkner, J.A., 1989. Muscle transplantation between young and old rats: age of host determines recovery. *The American Journal of Physiology* 256(6 Pt 1):C1262–C1266.
- [28] Cederna, P.S., Asato, H., Gu, X., van der Meulen, J., Kuzon Jr., W.M., Carlson, B.M., et al., 2001. Motor unit properties of nerve-intact extensor digitorum longus muscle grafts in young and old rats. *The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* 56(6):B254–B258.
- [29] Conboy, I.M., Conboy, M.J., Wagers, A.J., Girma, E.R., Weissman, I.L., Rando, T.A., 2005. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature* 433(7027):760–764.